Similar articles for PMID: 20811403

Year	Number of Results
1972	1
1995	1
1996	1
2002	3
2003	13
2004	9
2005	16
2006	10
2007	12
2008	6
2009	9
2010	21
2011	16
2012	15
2013	37
2014	40
2015	37
2016	23
2017	29
2018	18
2019	29
2020	25
2021	14
2022	11
2023	6
2024	0

1

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, Slader C, Field C, Dang P, Filshie RJ, Mills AK, Grigg AP, Melo JV, Hughes TP. Ross DM, et al. Leukemia. 2010 Oct;24(10):1719-24. doi: 10.1038/leu.2010.185. Epub 2010 Sep 2. Leukemia. 2010. PMID: 20811403

2

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.

Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, König H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A. Paschka P, et al. Leukemia. 2003 Sep;17(9):1687-94. doi: 10.1038/sj.leu.2403033. Leukemia. 2003. PMID: 12970765

3

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.

Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A. Merx K, et al. Leukemia. 2002 Sep;16(9):1579-83. doi: 10.1038/sj.leu.2402680. Leukemia. 2002. PMID: 12200666 Clinical Trial.

4

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P; Intergroupe Français des Leucémies Myéloïdes Chroniques. Mahon FX, et al. Lancet Oncol. 2010 Nov;11(11):1029-35. doi: 10.1016/S1470-2045(10)70233-3. Epub 2010 Oct 19. Lancet Oncol. 2010. PMID: 20965785 Clinical Trial.

5

Hematological and molecular response evaluation of CML patients on imatinib.

Gupta A, Prasad K. Gupta A, et al. J Assoc Physicians India. 2007 Feb;55:109-13. J Assoc Physicians India. 2007. PMID: 17571739

6

Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.

Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B, Kobbe G, Bornhäuser M, Hochhaus A, Ullmann AJ, Kindler T, Haus U, Gschaidmeier H, Huber C, Fischer T. Hess G, et al. J Clin Oncol. 2005 Oct 20;23(30):7583-93. doi: 10.1200/JCO.2005.01.3110. J Clin Oncol. 2005. PMID: 16234522 Clinical Trial.

7

BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.

Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K, Hughes T. Branford S, et al. Clin Cancer Res. 2007 Dec 1;13(23):7080-5. doi: 10.1158/1078-0432.CCR-07-0844. Clin Cancer Res. 2007. PMID: 18056186 Clinical Trial.

8

Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.

DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, Parekkedon B, Ritz J, Antin JH, Stone RM, Soiffer RJ. DeAngelo DJ, et al. Clin Cancer Res. 2004 Aug 1;10(15):5065-71. doi: 10.1158/1078-0432.CCR-03-0580. Clin Cancer Res. 2004. PMID: 15297408

9

[Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].

Qin YZ, Ruan GR, Liu YR, Li JL, Fu JY, Wang H, Chang Y, Jiang B, Jiang Q, Jiang H, Qiu JY, Chen SS, Lu DP. Qin YZ, et al. Zhonghua Xue Ye Xue Za Zhi. 2005 Jan;26(1):1-5. Zhonghua Xue Ye Xue Za Zhi. 2005. PMID: 15946498 Chinese.

10

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.

Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A. Lahaye T, et al. Cancer. 2005 Apr 15;103(8):1659-69. doi: 10.1002/cncr.20922. Cancer. 2005. PMID: 15747376 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

351 results

Results by year